Collplant Biotechnologies

CLGN · NASDAQ

$3.88+$0.00 (+0.00%)TodayMarket closed ·
Prev close $3.88

About CLGN

CollPlant Biotechnologies Ltd. operates as a regenerative and aesthetic medicine company. The company is headquartered in Rehovot, Central(Hamerkaz) and currently employs 39 full-time employees. The firm provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen).

Employees
39
Headquarters
Rehovot, Central(HaMerkaz)
Listed
Sep 1, 1993
Sector
Health Care
Industry
Biotechnology

Leadership

Collplant Biotechnologies executives
NameTitleSince
Roger Pomerantz——
Yehiel Tal——
Eran Rotem——
Ilana Belzer——
Hadas Dreiher Horowitz——
Bowman Bagley——
Philippe Bensimon——
Nadav Orr——
Oded Shoseyov—2008
Gili Hart——
Abraham Havron——
Alisa Lask——
Elan Penn——
Joseph Zarzewsky——

Revenue by product and region

Fiscal year ended Dec 31, 2024: $515.00K total revenue

By region

  • United states [Member]$484.00K94.0%
  • Israel [Member]$31.00K6.0%

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Collplant Biotechnologies suppliers and customers
CompanyRelationshipCorrelation
3D Systems DDDSupplier and customer0.88
United Therapeutics Corp UTHRSupplier and customer0.14
AbbVie ABBVSupplier and customer-0.83
Meitav Dash Investments MTDSSupplier and customer—
Hebrew University of JerusalemSupplier and customer—
Arthrex, Inc.Customer—
Stemcell Technologies, Inc.Customer—
Advanced Regenerative Manufacturing Institute, Inc.Supplier and customer—
RegenMed Development OrganizationSupplier and customer—

Similar companies

Companies in the same industry as Collplant Biotechnologies

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.